Resmed Inc at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript

Mar 21, 2023 / 07:45PM GMT
Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

Good afternoon, everyone. Welcome to the KeyBank Life Sciences and MedTech Investor Forum. My name is Matt Mishan. I'm our senior Medtech Analyst. I'm pleased to be joined by ResMed, who is represented today by Rob Douglas, President and COO. I'm going to start us off, but this will be 100% Q&A and questions can be submitted directly to me by typing into the box below under your video screen and then I can relay.

Rob, welcome. Thank you very much for joining. Very much appreciate it.

Robert A. Douglas - ResMed Inc. - President & COO

Thank you.

Questions and Answers:

Matthew Ian Mishan - KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

I'll start us off a little like with a broader question, just how would you compare the current environment and your level of visibility for the start of 2023 to the last couple of years?

Robert A.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot